Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Eur Urol. 2016 Dec 12;71(6):874–882. doi: 10.1016/j.eururo.2016.11.024

Fig. 4.

Fig. 4

Nuclear-specific AR-V7 localization is necessary for prediction of a treatment-specific reduction in risk of death. Individual covariates were tested for additive power in predicting outcome using a Cox proportional hazards model. The p values are the result of compensating for the other factors listed. The interaction of therapy and AR-V7 status was further investigated using a multivariable Cox proportional hazards model. The forest plot shows the hazard ratio and 95% confidence interval (CI) for (A) a cohort evaluated for AR-V7 positivity utilizing nuclear-specific localization and (B) a cohort evaluated for positivity utilizing nuclear-agnostic localization. ARSi = androgen receptor signaling inhibitor; PSA = prostate-specific antigen; phos. = phosphatase; LDH = lactate dehydrogenase.